Can Mobotinib be purchased in the country?

Mobotinib has been officially launched in China. This major news brings hope to many adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR 20 exon insertion mutations. The emergence of this innovative drug undoubtedly provides patients with new treatment strategies and options, allowing them to see more possibilities on the road to fighting cancer.

According to the authoritative release of the National Medical Products Administration (NMPA), mobotinib has successfully passed priority review and received the honor of conditional approval for marketing. The efficient advancement of this process reflects the country's great emphasis on new drug research and development and innovation, and also brings more timely treatment opportunities to patients.

Although Mobotinib is already on the market in China, it has not yet been included in the domestic medical insurance system. This means that when patients choose this drug, they need to bear all the drug expenses themselves and cannot enjoy the preferential policies of medical insurance.

For many patients who require long-term treatment, this undoubtedly adds considerable financial pressure. Mobotinib, as an imported innovative drug, has high research and development costs, so the market price is relatively high. According to the current market conditions, the cost of a course of Mobotinib is likely to be as high as tens of thousands of yuan.

But what we should look forward to is that with the increasing improvement of the national medical security system and the continuous emphasis on and support for innovative drugs, high-value drugs such as Mobotinib are very likely to be gradually included in the scope of medical insurance in the future. Such policy adjustments will greatly ease the financial pressure on patients, allowing more patients to easily obtain and benefit from this advanced treatment drug.